Relay Therapeutics, Inc. (RLAY)

Over the past six months, Relay Therapeutics' stock has increased by 106.64%. The share price increased by 337.97% from May 7, 2025, to May 6, 2026. In Q1 2026, the company reported a quarterly loss of $0.41 per share, missing estimates, with revenues of $3 million, also falling short of estimates. In February 2026, Relay Therapeutics outlined anticipated 2026 clinical milestones for its zovegalisib program, which recently received Breakthrough Therapy designation from the FDA. In April 2026, Relay Therapeutics' stock cleared a key benchmark, achieving a 90-plus RS Rating and demonstrating market leadership with a jump to a 94 RS Rating.

As a clinical-stage precision medicines company, Relay Therapeutics, Inc. is primarily focused on research and development with products in clinical trials and not yet commercialized. Therefore, there is no discernible demand seasonality for Relay Therapeutics' products and services at this time.

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery to develop life-changing therapies, operating in the Healthcare sector, specifically Biotechnology and Discovery Tools. The company utilizes its Dynamo™ platform to address previously intractable protein targets. Its major product candidates include RLY-2608 (zovegalisib), RLY-8161, Lirafugratinib (RLY-4008), and an αGal chaperone program. Relay Therapeutics has collaboration and license agreements with D. E. Shaw Research, LLC, Elevar Therapeutics, Inc., and Pfizer Inc.

Relay Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States. The company conducts a global Phase 1/2 clinical trial for zovegalisib in vascular anomalies.

Relay Therapeutics' brand reputation in the past year appears to be positively influenced by its scientific advancements and clinical progress, including the FDA Breakthrough Therapy designation for zovegalisib. The stock's strong performance and market leadership recognition also suggest a favorable perception among investors.

Relay Therapeutics, Inc. has a diverse ownership structure, with a significant portion held by institutional investors, ranging from 22.09% to 96.98%. Insiders hold around 2.20% to 24.85%, while public companies and individual investors own approximately 12.38% to 75.71% of the stock. Major institutional owners include Sb Investment Advisers (uk) Ltd, Commodore Capital Lp, Point72 Asset Management, L.P., BlackRock, Inc., Casdin Capital, LLC, Vanguard Group Inc, Bellevue Group AG, State Street Corp, Geode Capital Management, Llc, Spruce Street Capital LP, Dimensional Fund Advisors LP and Invesco Ltd. Significant individual or insider owners include Svf Pauling Cayman Ltd and Third Rock Ventures III LP.